bicalutamide has been researched along with afimoxifene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balbi, C; Barboro, P; Boccardo, F; Ferrari, N; Repaci, E; Rubagotti, A | 1 |
| Argellati, F; Boccardo, F; Mangerini, R; Pfeffer, U | 1 |
2 other study(ies) available for bicalutamide and afimoxifene
| Article | Year |
|---|---|
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Nucleus; Cell Survival; Estrogen Antagonists; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Male; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tamoxifen; Tosyl Compounds | 2011 |
Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds | 2012 |